Cara Therapeutics Inc., of Shelton, Conn., earned $2.5 million in milestone payments under its CR-845 development and licensing agreements with Maruishi Pharmaceutical Co. Ltd., of Japan, and Chong Kun Dang Pharmaceutical Corp. (CKD), of South Korea.